Approaches to circumvent tumor-mediated DC dysfunction can consist of DC vaccines or directly targeting and stimulating DCs in situ, by delivering DC-recruiting or promoting agents such as FLT3L, CpG, TLR and STING agonists (199). The gene discussed is FLT3LG; the disease is neoplasm.